Results 11 to 20 of about 425,308 (294)
Vaccines, 2023 We previously developed a polysaccharide-–RBD-conjugated nanoparticle vaccine which induced protective efficacy against SARS-CoV-2 in a mouse model. Here, we newly developed a vaccine, SCTV01A, by chemically conjugating recombinant SARS-CoV-2 RBD-Fc and ...
Chunyun Sun +11 more
doaj +1 more source
Challenges and developments in universal vaccine design against SARS-CoV-2 variants
npj Vaccines, 2022 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had become a global concern because of its unexpectedly high pathogenicity and transmissibility.
Fangxin Zhao +4 more
doaj +1 more source
A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. [PDF]
, 2015 Although recent methods for the engineering of antibody-drug conjugates (ADCs) have gone some way to addressing the challenging issues of ADC construction, significant hurdles still remain.
Caddick, S +5 more
core +1 more source
Microbiology Spectrum, 2014 ABSTRACTAdvanced molecular biology techniques developed during the past few decades have allowed the industry to exploit and commercialize the natural defense mechanisms that antibodies provide. This review discusses the latest advances in antibody-engineering technologies to enhance clinical efficacy and outcomes.
Kin-Ming, Lo +2 more
openaire +3 more sources
Antibody engineering & therapeutics, the annual meeting of the antibody society December 7-10, 2015, San Diego, CA, USA [PDF]
, 2016 The 26th Antibody Engineering & Therapeutics meeting, the annual meeting of The Antibody Society united over 800 participants from all over the world in San Diego from 6-10 December 2015.
Bakker, J +9 more
core +1 more source
Viruses, 2021 Lassa virus (LASV) is a rodent-borne arenavirus circulating in West African regions that causes Lassa fever (LF). LF is normally asymptomatic at the initial infection stage, but can progress to severe disease with multiorgan collapse and hemorrhagic ...
Meirong Wang +8 more
doaj +1 more source
Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? [PDF]
, 2008 Antibody-based therapeutics currently enjoy unprecedented success, growth in research and revenues, and recognition of their potential. It appears that the promise of the "magic bullet" has largely been realized.
Dimitrov, Dimiter S, Marks, James D
core +1 more source
A comprehensive proteogenomic study of the human Brucella vaccine strain 104 M
BMC Genomics, 2017 Background Brucella spp. are Gram-negative, facultative intracellular pathogens that cause brucellosis in both humans and animals. The B. abortus vaccine strain 104 M is the only vaccine available in China for the prevention of brucellosis in humans ...
Xiaodong Zai +12 more
doaj +1 more source
Artificial Cells, Nanomedicine, and Biotechnology, 2023 Recent years have seen the development of a variety of mammalian library approaches for display and secretion mode. Advantages include library approaches for engineering, preservation of precious immune repertoires and their repeated interrogation, as ...
Ramona Gaa +7 more
doaj +1 more source
mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures. [PDF]
, 2016 Computational methods have traditionally struggled to predict the effect of mutations in antibody-antigen complexes on binding affinity. This has limited their usefulness during antibody engineering and development, and their ability to predict ...
Ascher, David B, Pires, Douglas EV
core +3 more sources